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Drugs that target the chief mediator of nuclear export, chromosome region maintenance 1 protein (CRM1) have potential as
therapeutics for leukemia, but existing CRM1 inhibitors show variable potencies and a broad range of cytotoxic effects. Here, we
report the structural analysis and antileukemic activity of a new generation of small-molecule inhibitors of CRM1. Designated
selective inhibitors of nuclear export (SINE), these compounds were developed using molecular modeling to screen a small virtual
library of compounds against the nuclear export signal (NES) groove of CRM1. The 2.2-Å crystal structure of the CRM1-Ran-RanBP1
complex bound to KPT-251, a representative molecule of this class of inhibitors, shows that the drug occupies part of the groove in
CRM1 that is usually occupied by the NES, but penetrates much deeper into the groove and blocks CRM1-directed protein export.
SINE inhibitors exhibit potent antileukemic activity, inducing apoptosis at nanomolar concentrations in a panel of 14 human acute
myeloid leukemia (AML) cell lines representing different molecular subtypes of the disease. When administered orally to
immunodeﬁcient mice engrafted with human AML cells, KPT-251 had potent antileukemic activity with negligible toxicity to normal
hematopoietic cells. Thus, KPT-SINE CRM1 antagonists represent a novel class of drugs that warrant further testing in AML patients.
Leukemia (2013) 27, 66–74; doi:10.1038/leu.2012.219
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INTRODUCTION
Many types of proteins, including tumor suppressors and negative
regulators of the cell cycle, must localize to the cell nucleus to
function properly. During cancer initiation or progression,
malignant cells appear to acquire the ability to export key nuclear
proteins that inﬂuence treatment outcome.
1 In eukaryotic cells,
the chief mediator of protein export from the nucleus to the
cytoplasm is chromosome region maintenance 1 protein (CRM1),
also called exportin 1 (Xpo1). CRM1 is a member of the importin b
superfamily of nuclear export receptors (karyopherins) that can
interact with leucine-rich nuclear export signals (NESs).
2–6 These
targeting signals, consisting of 10- to 15-residue-long motifs
spanning four or ﬁve spaced hydrophobic amino acids,
6,7 bind to
the hydrophobic groove of CRM1.
8–10 Subsequent interaction of
the NES-directed protein cargo with the small GTPase molecule
Ran leads to cytoplasmic transport via a nuclear pore complex.
6,7
These observations have stimulated considerable interest in drugs
that block the CRM1-mediated export of tumor suppressors or
other proteins with potential importance in the growth and
survival of cancer cells.
Small molecule CRM1 inhibitors such as leptomycin B, ratjadone,
anguinomycin, goniothalamin, N-azolylacrylates, KOS-2464 and
CBS9106
11–17 bind covalently to a reactive-site cysteine residue
(Cys528), which is located in the NES-binding groove of human
CRM1.
9,10,18 This interaction restores nuclear localization and the
functions of speciﬁc cargo proteins that are mislocalized in cancer
cells. For example, leptomycin B causes nuclear retention of the
BCR-ABL1 fusion protein and activates apoptosis when
administered with the antileukemic drug imatinib, whereas
nuclear retention of topoisomerase IIa after treatment with
CRM1 inhibitors sensitizes multiple myeloma cells to etoposide
and doxorubicin.
19–22 Despite their ability to counteract the
nuclear export of critical proteins, CRM1 inhibitors that target
Cys528 residue show different potencies, diverse cargo protein
inhibition proﬁles and a broad range of toxic effects.
14,23,24
Moreover, it is not clear whether these drugs block binding to
cargo proteins by inducing conformational changes in the NES-
binding groove or the overall structure of CRM1 or by acting as
NES mimics or perhaps allosteric inhibitors. These caveats suggest
that the design of Cys528-targeted CRM1 inhibitors could be
optimized, thus signiﬁcantly improving their activity and reducing
toxicities.
Here, we report a structural analysis and the antileukemic
activity of a new generation of potent and irreversible small-
molecule, selective inhibitors of nuclear export (SINE) that
irreversibly block CRM1. These SINE compounds were discovered
through an in silico molecular modeling strategy, based on our
recently published structure,
9 in which a docking-and-binding
mode analysis was used to screen a small virtual library of
compounds against the NES groove of CRM1. The resultant
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www.nature.com/leuinhibitors irreversibly inactivate CRM1-directed protein export by
covalent modiﬁcation of the essential CRM1-cargo-binding
residue Cys528. In this report, we present the 2.2-Å crystal
structure of the CRM1-Ran-RanBP1 complex bound to KPT-251, a
representative molecule of this class. We also show that these
small molecules are highly active in inducing apoptosis in
preclinical models of acute myeloid leukemia (AML), without
affecting normal cells, including maturing or differentiated normal
hematopoietic cells.
MATERIALS AND METHODS
Cloning, expression and protein puriﬁcation
HsRan was cloned into the pET18 vector.
ScCRM1 and
ScRanBP1 were cloned
into a pGEX-4t-3 based expression vector incorporating a TEV-cleavable
N-terminal GST-tag fusion. Residues 377–413 of
ScCRM1 were removed as
previously described.
25 To generate inhibitor-accessible
ScCRM1, Thr539
was mutated to cysteine.
ScCRM1,
ScRanBP1 and
HsRan were expressed
separately in Escherichia coli BL-21 (DE3) following induction with 0.5mM
isopropyl b-D-1-thiogalactopyranoside for 10h at 251C. Cells were
harvested and lyzed in buffer containing 50mM sodium Tris pH 7.5,
10% glycerol, 5mM dithiothreitol, 200mM NaCl and protease inhibitors.
After centrifugation,
ScCRM1-GST and
ScRanBP1-GST supernatants were
loaded onto GSH beads. Following extensive washing,
ScCRM1 and
ScRanBP1 were cleaved off the glutathione sepharose beads with TEV
protease and further puriﬁed by gel ﬁltration chromatography in buffer
containing 10mM Tris (pH 7.5), 100mM NaCl, 5mM MgCl2.
HsRan-his was
loaded onto Ni-NTA beads, washed with lysis buffer, added with 20mM
imidazole and eluted with buffer containing 20mM sodium Tris (pH 7.5),
10% glycerol, 200mM imidazole, 200mM NaCl, and further puriﬁed gel
ﬁltration in buffer containing 10mM Tris (pH 7.5), 100mM NaCl, 5mM MgCl2.
Crystallization and data collection
HsRan was loaded with GMP-PNP as previously described.
26 The
ScCRM1(T539C) 
HsRan 
ScRanBP1 complex was obtained by mixing the
three proteins at 1:2:1.5 molar ratio followed by gel ﬁltration
chromatography. The puriﬁed protein complexes were then mixed with
KPT-251 (dissolved in 100% ethanol to B10mM) at 1:2 molar ratio.
The KPT-251 
ScCRM1(T539C) 
HsRan 
ScRanBP1 complex was crystallized
using conditions similar to those used by Koyama and Matsuura
25
(reservoir solution contains 18% PEG3350, 200mM ammonium nitrate,
100mM Bis-Tris (pH 6.6)). The crystallization solutions were supplemented
with 20% (v/v) glycerol to cryo-protect the crystals. X-ray diffraction data
was collected at beamline 19ID, Advanced Photon Source (APS), Argonne,
IL, USA. Data collection statistics are listed in Supplementary Table 1.
Structure determination and reﬁnement
The KPT-251 
ScCRM1(T539C) 
HsRan 
ScRanBP1 structure was solved using
the molecular replacement program MolRep
27 and the coordinates of
ScCRM1 
ScRan 
ScRanBP1 (3M1I) as the search model.
25 One inhibitor
ScCRM1(T539C) 
HsRan 
ScRanBP1 complex is present in each asymmetric
unit. The resulting models and electron density maps were examined with
the program COOT.
28 Several cycles of model rebuilding and reﬁnement
using the program Refmac5 led to convergence.
29,30 Translation/Libration/
Screw (TLS) reﬁnement was used in the reﬁnement process.
29,31
Ramanchandran statistics were calculated using the CCP4 program
Procheck.
29,32 Reﬁnement statistics are listed in Supplementary Table 2.
Cell lines and cell viability assay
Cell lines were cultured in RPMI 1640 medium (Gibco, Grand Island, NY,
USA), supplemented with 10% fetal bovine serum and penicillin/
streptomycin. Cells were plated at a density of 10000 cells per well in a
96-well plate and incubated with DMSO or serial dilutions of KPT-185 for 3
days. The cell viability was measured using Cell Titer Glo assay (Promega,
Madison, WI, USA) and reported either as percentage of untreated (DMSO
control) cells or relative cell numbers. BCL2-overexpressing MV4-11 cells
were generated using MSCV retroviral expression system. Brieﬂy, 293T cells
were transfected with either BCL2-IRES-GFP MSCV or control MSCV vector
using retroviral system. The BCL2 and control viruses were introduced into
MV4-11 cells by spin inoculation at 1500g for 90min. MV4-11 cells infected
with BCL2 or control vector viruses were isolated by ﬂow cytometry sorting
and the expression of BCL2 conﬁrmed by western blot analysis using
human-speciﬁc Bcl-2 antibody (Cell Signaling, Danvers, MA, USA).
Apoptosis analysis
MEBCYTO Apoptosis Kit (MBL Co., Ltd, Nagoya, Japan) was used to detect
apoptotic cells by annexin V staining. Cells were co-incubated with annexin
V-ﬂuorescein isothiocynate (FITC) and propidium iodide (PI) and measured
by two-color FACS cytometry (BD FACS Canto, BD Biosciences, San Jose,
CA, USA). The percentage of annexin V and PI-positive cells was
determined based on the dot plots of FITC vs PI. Terminal dUTP nick
end-labeling (TUNEL) assay ApopTag Fluorescein Direct In Situ Apoptosis
Detection kit (Millipore, Billerica, MA, USA) was used to detect apoptotic
cells through staining of fragmented DNA. Brieﬂy, 2 10
6 MV4-11 cells,
treated with DMSO or KPT-185 for 24h, were washed with PBS, ﬁxed with
1% paraformaldehyde for 15min on ice and 70% ethanol for 2h at
 201C. The cells were then washed with PBS, incubated with terminal
deoxynucleotidyl (TdT) enzyme at 371C for 30min, anti-digoxigenin-
ﬂuorescein conjugate at 371C for 30min and PI/RNase solution at room
temperature for 15min according to the protocol for cell suspensions from
ApopTag Fluorescein Direct In Situ Apoptosis Detection kit (Millipore). The
cells were then subjected to FACS analysis to generate dot plots of TUNEL
(FITC) vs cell cycle stage (PI) (BD FACS Canto, BD Biosciences). The collected
FACS data were analyzed using BD FACSDiva Software (BD Biosciences) to
determine TUNEL positive events per cell cycle stage.
Cell cycle analysis
Cells were ﬁxed with 70% ethanol, incubated overnight at  201C, washed
with PBS and stained with PI/RNase staining buffer (BD Biosciences) for
15min at room temperature. Cells were analyzed by ﬂow cytometry using
BD FACS Canto (BD Biosciences). The DNA histograms were analyzed using
ModFit LT cell cycle analysis software (Verify Software House, Topsham,
ME, USA).
Xenograft models
2 10
6 luciferase-expressing MV4-11 cells were introduced into 7-week-
old female NOD-SCID-IL2Rcg
null (NSG) mice (The Jackson Laboratory, Bar
Harbor, ME, USA) via tail-vein injections. The tumor burden was assessed
by bioluminescence imaging (BLI) using a IVIS Spectrum system (Caliper
Life Sciences, Hopkinton, MA, USA) every 3–5 days. After leukemia,
establishment was documented by BLI, mice were split into two groups of
nine mice and treated by gavage either with vehicle control (Pluronic F-68/
PVP-K29/32) or KPT-251 at 75mg/kg/day three times per week for 5 weeks.
Blood counts were obtained after 4.5 weeks of treatment using Hemavet
950 F instrument (Drew Scientiﬁc, Dallas, TX, USA). After 5 weeks, spleen,
liver and femur from one mouse from control and each of the treatment
groups were preserved in 10% formalin for histopathology. Survival of the
drug-treated mice was measured as the time from initiation of therapy
until moribund state. Survival beneﬁt was assessed by Kaplan–Meier
analysis. Femur and spleen tissues were ﬁxed in 10% formalin, sectioned,
parafﬁn-embedded and stained with hematoxylin and eosin. Stained slides
were viewed and photographed using an Olympus BX41 microscope and
Q-color5 digital camera (Olympus, Center Valley, PA, USA) and imaged
using Adobe Photoshop CS4 software (Adobe, San Jose, CA, USA).
RESULTS
Novel CRM1 inhibitors of the KPT-SINE class
We developed a structural model of CRM1 in which the NES-
binding site is conformationally adapted for binding diverse
irreversible inhibitors. A unique structural feature of this con-
formation is a methionine switching motion involving Met545 and
Met583, which enables tighter binding and improved positioning
of the thiol-reactive warhead relative to the targeted Cys528. This
model was used as a structure-based framework for guiding the
optimization of our lead series of irreversible inhibitors, desig-
nated SINE.
1,33 KPT-251 was the result of efforts to optimize shape
complementarity, electrostatic interactions and metabolic stability
by replacement of the labile ester with an oxadiazole bioisostere.
The structures of KPT-251 and KPT-185 (Supplementary Figure S1)
illustrate the improved bioavailability of KPT-251 as a result of
Inhibition of CRM1-mediated nuclear export in AML
J Etchin et al
67
& 2013 Macmillan Publishers Limited Leukemia (2013) 66–74these structural modiﬁcations, with retention of the basic KPT-SINE
structure and the thiol-reactive warhead.
Structure of the KPT-251 CRM1 Ran RanBP1 complex
Shown in Figure 1 is the 2.2-Å crystal structure of KPT-251 bound
to the ternary complex of Saccharomyces cerevisiae CRM1
(
ScCRM1), S. cerevisiae RanBP1 (
ScRanBP1) and human RanGTP
(Figures 1a and b; Supplementary Table 1; Supplementary Figure S2).
Atomic coordinates and structure factors have been deposited in
the Protein Data Bank under the RCSB ID code rcsb074486 and
PDB ID code 4GPT. As
ScCRM1 has a threonine residue, Thr539, in
place of the reactive Cys528 in human CRM1, we mutated Thr539
to cysteine (
ScCRM1(T539C)) to mimic the human sequence and
enable covalent modiﬁcation by the inhibitor. The overall
structure of the KPT-251 
ScCRM1(T539C) Ran RanBP1 complex is
similar to the previously reported inhibitor-free
ScCRM1 Ran 
RanBP1 structure (Ca rmsd of 0.65Å).
25 KPT-251 binds in the
NES-binding groove, which is located on the central, convex side
of the CRM1 ring (Figures 1b and c and Supplementary Figure S3).
Figure 1. Structure of KPT-251 bound to CRM1. (a) Chemical structure of KPT-251. (b) KPT-251 (violet) binds in the NES-binding groove of
CRM1 (pink). Select inhibitor-CRM1 interactions (o4Å) are shown with dashed lines. (c) The overall structure of KPT-251 bound to the
ScCRM1(T539C)-
HsRan-
ScRanBP1 complex. A space-ﬁlling model of KPT-251 is shown together with CRM1 (pink), Ran (green) and RanBP1
(yellow). (d) Surface representation of the NES-binding groove of CRM1 in the inhibitor-free
ScCRM1-Ran-RanBP1 complex (3M1I). No ligand is
bound in the groove, but superimposed KPT-251 (white) is shown for comparison with panel (e). Helices and select side chains below the
surface are shown in cyan. (e) Surface representation of the KPT-251-bound CRM1 groove. (f) Surface representations of the
PKINES-bound
CRM1 groove (3NBY). The NES in the structure is removed. No inhibitor is bound in this groove, but superimposed KPT-251 (white) is shown to
facilitate comparison with panel (e). (g) Residues 570–605 of CRM1 in the
ScCRM1-Ran-RanBP1 complex and the KPT-251-
ScCRM1(T539C)-Ran-
RanBP1 structures were superimposed (Ca rmsd 0.33Å) and shown as cartoon representations to compare NES-binding grooves in the two
structures. (h) Superposition of the KPT-251- (pink) and
PKINES-bound (green) grooves. KPT-251 (violet) and the C539 residue (pink) are shown
as sticks. The panel on the right is rotated 901 about the vertical axis and helices H12A of the grooves in both structures were removed for a
clear side view of the ligands. The
PKINES and its hydrophobic side chains are bright green.
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ScCRM1 is
closed in the
ScCRM1-Ran-RanBP1 complex (Figures 1d and e).
25 In
the inhibited structure, the NES groove is opened to allow KPT-251
binding (Figure 1f).
KPT-251 is oriented with its bis-triﬂuoromethyl phenyl group
pointing towards the bottom of the CRM1 groove (N-terminal
ends of helices H11A and H12A), whereas its alkyl oxadiazole
group heads in the opposite direction (Figure 1b). Interactions
between KPT-251 and CRM1 are almost entirely of hydrophobic
nature, as the triazole and oxadiazole groups of KPT-251 make no
polar contacts with CRM1, indicating a binding mode distinct from
previously developed CRM1 inhibitors (Supplementary Table 2).
Structures of inhibitor-free and inhibitor-bound
ScCRM1 also
clearly indicate that the NES-binding groove is conformationally
quite plastic (Figures 1d–f). The 13-residue-long
PKIaNES peptide is
substantially larger than KPT-251 (Figure 1e) and occupies the
entire groove, burying 1117Å
2 of the CRM1 groove, whereas KPT-
251 buries only 420Å.
2 The inhibitor overlaps with three of the ﬁve
hydrophobic residues of the NES, but its triﬂuoromethyl phenyl
group penetrates much deeper into the groove than do the
NES side chains, possibly outcompeting nuclear export cargos
(Figures 1f–h).
KPT-185 inhibits CRM1-NES interactions and nuclear export
To assess the ability of KPT-SINE inhibitors to prevent CRM1 from
binding NES, we performed pull-down assays using puriﬁed
recombinant human CRM1 and an immobilized GST-NES. The
results showed that both leptomycin B and KPT-185 (Figure 2)
prevented interactions between CRM1 and the NES from the NPM
mutant protein, NPMcþ(mutA), which is frequently found in AML
cells (Figure 2a).
34 We also examined the subcellular localization of
the NPMcþ(mutA) protein when overexpressed in HeLa cells.
Wild-type NPM is localized to the nucleolus, but NPMcþ(mutA)
exhibited cytoplasmic localization, which was reversed by
treatment with either leptomycin B or KPT-185 (Figure 2b).
KPT-185 exhibits antileukemic activity
To investigate the antileukemic activity of our novel CRM1
inhibitors, we tested the effects of KPT-185 on the viability of 14
human AML cell lines. Dose–response measurements using serial
dilutions of KPT-185, from 1mM to 0.3nM, yielded IC50 values of
15–474nM after 3 days of exposure (Figure 3a; Supplementary
Table 3). The AML cell lines that tested in the sensitivity assays
represented different molecular subtypes of AML, including the
OCI-AML3 cell line expressing NPMcþ (Supplementary Table 3),
but there were no correlations between relative sensitivity
measurements and any of these molecular abnormalities, includ-
ing p53 mutations. For example, the MV4-11 cell line, which
expresses both the MLL-AF4 chimeric protein and FLT3-ITD
mutant receptor, demonstrated a high level of sensitivity to KPT-
185, despite the association of these abnormalities with high-risk
AML. To determine whether inhibition of cell growth due to CRM1
inhibition was due to induction of apoptosis, we measured the
expression of annexin V during KPT-185 treatment. High levels of
annexin V staining in the AML cells treated with KPT-185 indicated
that many of the cells had undergone apoptosis, with this fraction
increasing steadily with increasing concentrations of KPT-185
(Figure 3b and Supplementary Figures S4a–d). To address whether
the mitochondrial (intrinsic) apoptotic pathway was activated
upon CRM1 blockade, we overexpressed the anti-apoptotic
protein BCL2 in MV4-11 cells. Transduction of BCL2, but not
control vector, effectively suppressed the KPT-185-induced
apoptotic response in MV4-11 cells, indicating that CRM1
inhibition promotes cell death in AML cells via activation of
apoptosis through the intrinsic pathway, involving mitochondrial
permeabilization (Supplementary Figure S5).
KPT-185 promotes cell cycle arrest and apoptotic cell death in G1
phase
To examine the effect of CRM1 inhibitors on induction of
apoptosis during the cell cycle of AML cells, we performed DNA
histogram and TUNEL analyses. Cell cycle distribution was
determined by DNA PI staining of MV4-11 cells incubated with
different concentrations of KPT-185 for 24h. As shown in
Figure 3c, MV4-11 cells undergo G1 cell cycle arrest, with
increased fraction of cells in G1 and a decreased fraction in
S and G2/M phases in response to 30nM KPT-185 (Figure 3c). Cells
accumulated in both G1 and S upon incubation with higher
concentrations of KPT-185 (60 and 120nM), indicating cell cycle
arrest in both of these phases (Figure 3c). We also observed a
dose-dependent accumulation of pyknotic cells in the sub-G1
induced by incubation with KPT-185, consistent with the levels of
annexin V staining (Figures 3b and c). Finally, to assess the
distribution of apoptotic cells within the cell cycle upon treatment
with KPT-185, we performed TUNEL assay, combined with PI
staining. TUNEL/PI labeling after incubation of the MV4-11 cells
with 60nM KPT-185 for 24h demonstrated that treatment with this
CRM1 inhibitor induces apoptosis primarily at the G1 stage of the
cell cycle (Figures 3d and e).
Striking activity of KPT-251 against leukemic cells in vivo
To assess the activity of the CRM1 inhibitor KPT-251 against
both leukemic and normal hematopoietic cells in vivo,
we transplanted MV4-11 cells expressing luciferase into NOD-
SCID-IL2Rg
null (NSG) mice, enabling us to quantify leukemia
growth in vivo by serial BLI. Mice with established leukemia
(Supplementary Figure S6) were treated with either vehicle or
KPT-251 (75mg/kg) three times a week for 5 weeks. This treatment
led to striking suppression of the MV4-11 leukemia growth in vivo,
as indicated by the marked increase in BLI signal in leukemic
mice treated with vehicle control, and lack of BLI increase
in mice treated with KPT-251 (Figures 4a and b). As a result,
vehicle-treated mice became moribund or died after 35 days
of treatment, whereas KPT-251-treated mice exhibited
signiﬁcantly increased survival (Figure 4c), with leukemia progres-
sion occurring only after cessation of treatment, as assessed using
BLI (Figure 4b), and conﬁrmed using histopathologic analysis
below.
Importantly, KPT-SINE CRM1 inhibitors exhibited only minimal
toxicity against normal hematopoietic cells. This conclusion is
based on the effects of 35 days of treatment on the circulating
white blood cells, neutrophils, lymphocytes and platelets
and on the hematocrit and reticulocyte percentages of inhibitor-
treated compared with vehicle-treated mice (Figure 5). Bone
marrow histopathology after 35 days of treatment with KPT-251
or vehicle showed a striking decrease in the extent of leukemia
cell inﬁltration in KPT-treated mice versus vehicle-treated mice. At
this time, the vehicle-treated mice were moribund due to
leukemia, and the bone marrow showed almost complete
inﬁltration by the human MV4-11 AML cells (Figure 6a).
Besides the very low levels of leukemic cell inﬁltration in the
bone marrow of the inhibitor-treated mice, these biopsies
also showed normal hematopoietic cell morphology and
cellularity, including developing cells within the myeloid, erythroid
and megakaryocytic lineages (Figure 6b). Histopathologic
analysis of the spleens of these mice showed similar ﬁndings,
with extensive leukemic cell replacement in vehicle-treated
mice and low levels of leukemic cells with prominent extra-
medullary hematopoiesis in inhibitor-treated mice (Figures 6c and d).
The dose-limiting toxicity of this class of CRM1 inhibitors in
mice is weight loss, and at the dosages administered here weight
loss was remediated by caloric supplementation (Supplementary
Figure 7).
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& 2013 Macmillan Publishers Limited Leukemia (2013) 66–74Figure 2. KPT-185 inhibits CRM1-cargo interactions and nuclear export. (a) GST fusion of the NPMcþ(mutA) NES was immobilized on
glutathione sepharose and then incubated with 10mM CRM1 proteins that were preincubated with either buffer or inhibitors (20mM LMB or
200mM KPT-185, an analog of KPT-251) and molar excess of RanGTP. After extensive washing, a fraction of the bound proteins was visualized
by SDS-PAGE and coomasie blue staining. (b) EGFP-NPM (wild type) is localized in the nucleolus when transfected into HeLa cells, whereas a
mutant of NPM found in AML called NPMcþ(MutA) is mislocalized to the cytoplasm. Treatment of 10nM leptomycin B or 100nM KPT-185
reverted the mislocalization such that EGFP-NPMcþ(mutA) is now back in the nucleus.
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Our ﬁndings establish the potency and speciﬁcity of a newly
generated group of CRM1 inhibitors and demonstrate their
antileukemic efﬁcacy against AML cells, both in vitro and in a
preclinical model. The design of these compounds is based on the
integration of in silico molecular modeling with computational
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Figure 6. KPT-251 prevents inﬁltration of leukemia cells into mouse bone marrow and spleen. (a, b) Hematoxylin and eosin staining of 4mm
parafﬁn-embedded femur sections isolated from mice treated with vehicle (a) or KPT-251 at 75mg/kg (b). Bone marrow of vehicle-treated mice
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to previously published CRM1 inhibitors.
11–13,15–17 The 2.2-Å
crystal structure of KPT-251 bound to a CRM1-Ran-RanBP1
complex (Figure 1) demonstrates that CRM1 inhibitor interactions
are almost entirely hydrophobic in nature and that KPT-251 ﬁlls
the space that is usually occupied by the C-terminal third of an
NES peptide. The KPT-251-bound CRM1 groove is narrower and
deeper than the NES-bound groove, suggesting that the former
groove is conformationally plastic. The triﬂuoromethyl phenyl
group of KPT-251 penetrates much deeper into the groove than
do the NES side chains, possibly contributing to the potency of the
compound in outcompeting the cargo proteins typically exported
from the nucleus.
The CRM1 inhibitors we describe possess striking antileukemic
activity against human AML lines that carry different underlying
molecular abnormalities, suggesting their potential value in
treatment of a broad spectrum of AML subtypes. Previous studies
with CRM1 inhibitors that either irreversibly (LMB, ratjadone,
anguinomycin and goniothalamin) or reversibly (CBS9106) bind to
Cys528 in the NES-binding groove of CRM1 also demonstrated
anticancer cell activity. However, their signiﬁcant toxicity in
in vivo studies has curtailed their translation to clinically useful
agents.
11–13,15–17 By contrast, KPT-251 was strikingly active against
human AML cells in a xenograft model, with only minimal toxicity
to normal tissues, including normal circulating blood cells and
bone marrow cells. Thus, the increased speciﬁcity of these
compounds compared with their predecessors appears to have
eliminated one of the major obstacles to clinical exploitation of
this class of anticancer drugs. Our results reported here and those
recently published by other investigators
33 relate speciﬁcally to
the efﬁcacy of KPT-SINE inhibitors in inducing cytotoxicity in
human AML cells, but other ongoing studies indicate striking
activity against other types of hematologic neoplasms. Along
these lines, KPT-330, closely related to KPT-251 but with superior
pharmacokinetic properties, has entered phase 1 clinical trials in
humans with advanced cancers.
The best-known abnormality of nuclear-cytoplasmic transport in
AML involves the mutant NPM1 protein, which is found in the
malignant clones of 30% of AML patients. This mutation creates an
additional NES motif in NPM1 that results in enhanced CRM1-
dependent transport of the protein to the cytoplasm, together
with the transport of wild-type NPM1 as a heterodimer with the
mutant.
35 We show antileukemic activity by KPT-SINE not only
against OCI-AML3 cells, the only human cell line with the NPMcþ
mutation, but also against cell lines lacking this mutation. Thus,
the activity of KPT-SINE compounds must also involve defects in
nuclear-cytoplasmic trafﬁcking of proteins other than
NPMcþpossibly tumor suppressors, that are retained in the
nucleus and are uniquely toxic in malignant compared with
normal hematopoietic progenitor cells.
Our data indicate that these CRM1 inhibitors induce cell cycle
arrest in G1 phase of the cell cycle in AML cells, inducing S phase
delay only at high concentrations. These inhibitors also induce
apoptosis throughout each phase of the cell cycle, most
signiﬁcantly in the G1 phase, in contrast to other compounds
with activity against AML cells, which are relatively speciﬁc for
actively cycling cells. Our observation of the apoptotic response to
KPT-185 in BCL2-overexpressing MV4-11 cells suggests that
apoptosis occurs via the intrinsic mitochondrial pathway.
36 The
mechanism that protects normal hematopoietic cells from
apoptotic death during treatment with these CRM1 inhibitors is
an important question of investigation of future studies.
One possibility is that leukemia cells are ‘primed’ to undergo
apoptosis,
37 so that inhibition of CRM1 by KPT-SINE provides
additional apoptotic signals that are sufﬁcient to induce apoptosis
in leukemic, but not normal blood cells. Further investigation of
the mechanisms by which CRM1 inhibitors speciﬁcally induce the
death of AML cells will help to clarify their single-agent activity
and thus how they can be most effectively integrated into
regimens now in use to treat patients with AML.
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